Follow-Up Strategy for Bone Lesions After 12 Months of Zoledronic Acid

Treatment Duration and De-escalation Strategy

The European Society for Medical Oncology recommends continuing zoledronic acid rather than stopping after 12 months, as discontinuation is not recommended except in patients with oligometastatic bone disease in complete remission 1
Patients can safely de-escalate to every 12-week dosing rather than discontinuing therapy, provided their bone disease is well-controlled by antineoplastic treatment and they have not experienced recent skeletal-related events (SREs) 1
The decision to continue versus de-escalate depends on several clinical factors, including bone disease control, recent SREs, and progression of underlying bone metastases 2, 3, 4

The ZOOM trial demonstrated that extending zoledronic acid to every 12 weeks after 12-15 months of monthly treatment resulted in similar skeletal morbidity rates compared to continued monthly dosing 2, 3, 4
Bone turnover markers were higher with 12-weekly dosing, which requires monitoring 2, 3, 4

The American Society of Clinical Oncology recommends monitoring serum calcium before each infusion to prevent hypocalcemia 1, 6
Renal function (serum creatinine) should be monitored before each dose 6
Vitamin D levels should be monitored intermittently to ensure adequacy 6

The National Comprehensive Cancer Network recommends continuing dental monitoring every 6 months to detect early signs of osteonecrosis of the jaw (ONJ) 6, 7
Avoid invasive dental procedures when possible, and if necessary, defer resuming zoledronic acid until complete healing is confirmed 7

For multiple myeloma, bisphosphonate therapy can be interrupted after 2 years in patients in remission 1
For breast and prostate cancer, continue therapy throughout the course of disease unless there is substantial decline in performance status 1, 2, 3, 4

Do not discontinue therapy arbitrarily based solely on duration; continue until disease remission or performance status decline 1
Do not extend denosumab dosing intervals if the patient switches agents—denosumab requires continuous monthly dosing unlike bisphosphonates 2, 3, 4
Do not ignore elevated bone turnover markers when considering de-escalation, as this predicts higher SRE risk 2, 3, 4